Add a Thiazide or Thiazide-Like Diuretic to the Current Regimen
The next step is to add a thiazide or thiazide-like diuretic (preferably chlorthalidone or indapamide) to the current regimen of amlodipine 5 mg and losartan 100 mg. This patient is currently on dual therapy with an ARB and a calcium channel blocker, which represents step 2 of the standard treatment algorithm for non-Black patients according to the 2020 ISH guidelines 1.
Rationale Based on Treatment Algorithm
The 2020 International Society of Hypertension guidelines provide a clear stepwise approach for non-Black patients 1:
- Step 1: Low-dose ACEi/ARB
- Step 2: Add DHP-CCB (calcium channel blocker)
- Step 3: Increase to full dose
- Step 4: Add thiazide/thiazide-like diuretic
- Step 5: Add spironolactone or alternatives
Your patient is currently on losartan 100 mg (full-dose ARB) plus amlodipine 5 mg (half-dose CCB). Before adding a third drug class, you should first optimize the amlodipine dose to 10 mg daily 2, as the FDA-approved maximum antihypertensive dose is 10 mg once daily, and most patients require this higher dose for adequate effect.
Specific Action Plan
Immediate Steps:
First, increase amlodipine from 5 mg to 10 mg daily and reassess BP in 7-14 days 2
- The FDA label indicates titration can occur more rapidly if clinically warranted with frequent assessment
- If BP remains elevated after this optimization, proceed to step 2
Add a thiazide-like diuretic - specifically chlorthalidone (12.5-25 mg daily) or indapamide (1.25-2.5 mg daily)
- These are preferred over hydrochlorothiazide due to longer duration of action and superior cardiovascular outcomes
- The 2020 ISH guidelines specifically recommend thiazide-like diuretics at this step 1
Critical Considerations Before Adding Therapy:
Check medication adherence first 1, 3 - approximately 20% of apparent treatment resistance is due to non-adherence. Consider:
- Direct questioning about missed doses
- Pill counts
- Home BP monitoring to exclude white-coat effect
- Review of interfering medications (NSAIDs, decongestants, oral contraceptives)
Confirm true hypertension with home BP monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) 1 to exclude white-coat hypertension, which affects up to 30% of patients with apparent treatment resistance.
Assess for secondary causes if BP remains uncontrolled, particularly:
- Primary aldosteronism (most common)
- Obstructive sleep apnea
- Renal artery stenosis
- Chronic kidney disease
If BP Remains Uncontrolled After Triple Therapy
Should the patient remain hypertensive despite optimized triple therapy (ARB + CCB + thiazide-like diuretic at maximum tolerated doses), this constitutes resistant hypertension 4, 3.
The next step would be adding a mineralocorticoid receptor antagonist (MRA) - specifically spironolactone 25-50 mg daily (if eGFR ≥45 mL/min/1.73 m²) 4, 3. The 2025 AHA/ACC guidelines strongly recommend MRA addition as the fourth agent in resistant hypertension, as it addresses the aldosterone excess commonly present in treatment-resistant cases.
Common Pitfalls to Avoid
- Don't add multiple drugs simultaneously - this makes it impossible to identify which agent caused side effects or therapeutic benefit
- Don't use hydrochlorothiazide - chlorthalidone and indapamide are superior for cardiovascular outcomes
- Don't forget lifestyle modifications - sodium restriction (<2400 mg/day), weight loss if overweight, regular exercise, and limiting alcohol remain essential 3
- Don't delay referral - if BP remains uncontrolled after 3 months of optimized therapy, refer to a hypertension specialist 1
Target Blood Pressure
Aim for BP <130/80 mmHg 1 in most patients, with individualization for elderly or frail patients. The goal should be achieved within 3 months of treatment optimization 1.